Sex-Specific Regulation of Angiogenin in Alzheimer’s Disease

Why It Matters

These findings reveal a sex‑specific molecular axis that could be leveraged for precision AD therapies, highlighting ANG as a novel therapeutic target especially for women who bear a disproportionate disease burden.

Key Takeaways

• Female AD patients split into three ANG‑based molecular subtypes.
• High ANG correlates with lower inflammation and slower cognitive decline.
• Male AD brains show reduced ANG protein compared with controls.
• ANG‑derived tiRNA‑Gly‑GCC suppresses apoptosis via apoptosome inhibition.
• Targeting ANG pathways may enable sex‑specific AD therapeutics.

Pulse Analysis

Alzheimer’s disease exhibits pronounced sex differences, with women facing higher incidence and faster cognitive deterioration. Angiogenin (ANG), a 14 kDa ribonuclease that generates protective tRNA‑derived fragments under stress, has been implicated in neurodegenerative conditions but its role in AD remained unclear. By integrating cell‑culture experiments, an AD mouse model, and extensive human brain datasets, investigators uncovered that ANG’s regulation diverges sharply between males and females, offering a molecular explanation for observed clinical disparities.

In a comprehensive analysis of 645 postmortem and transcriptomic samples, the team identified three female‑specific ANG subtypes. Low ANG expression coincided with heightened inflammatory markers and increased neuronal apoptosis, while intermediate levels showed mixed pathology. The most striking group—high ANG expression—exhibited dampened NLRP3 inflammasome activity, elevated antioxidant Nrf2 signaling, and a measurable slowdown in cognitive decline, translating into extended survival. Male subjects, by contrast, consistently displayed reduced ANG protein, suggesting a distinct pathogenic trajectory that does not involve the protective tiRNA‑Gly‑GCC axis.

These insights open new avenues for precision medicine in AD. Therapeutic strategies that boost ANG activity or mimic its tiRNA products could selectively benefit women, potentially mitigating inflammation and apoptosis. Moreover, the sex‑specific nature of ANG regulation underscores the necessity of stratifying clinical trials by gender to capture differential responses. Future research should explore ANG‑targeted compounds, assess their safety in neurodegenerative contexts, and determine how they interact with existing anti‑amyloid or tau‑directed therapies.